Arrhythmia care company Acutus Medical revealed on Thursday that it has obtained CE mark approval in Europe for its AcQMap contact mapping software.

The new software offers expanded functionality which provides physicians with more options to inform individualised therapy.

AcQMap enables physicians to uncover the electrical activation pattern of the heart with real-time visualisation during electrophysiology procedures. With non-contact mapping, physicians see full-chamber, continuous beat-by-beat arrhythmia conduction and can locate arrhythmias outside the pulmonary veins to inform their treatment strategy, enabling an iterative map-ablate-remap approach.

According to Acutus Medical, the contact mapping software is compatible with both first and second generation AcQMap platforms and will be installed on all European systems in Q3.

Additionally, the US FDA has cleared the company's second generation AcQMap platform. All AcQMap systems retain the unique ability to quickly reconstruct atrial anatomy using ultrasound and map electrical patterns using non-contact, charge density technology, creating ultra-high-resolution 3D images in real time.

The second generation AcQMap system is built to support future software innovations and will be available in the US in Q3.

Cardiac ablation treatment can improve quality of life for patients with atrial arrhythmias including atrial fibrillation (AF). AF affects more than 33 million people globally and increases the risk of stroke and heart failure.